Page last updated: 2024-11-05

thalidomide and HIV Wasting Syndrome

thalidomide has been researched along with HIV Wasting Syndrome in 25 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

HIV Wasting Syndrome: Involuntary weight loss of greater than 10 percent associated with intermittent or constant fever and chronic diarrhea or fatigue for more than 30 days in the absence of a defined cause other than HIV infection. A constant feature is major muscle wasting with scattered myofiber degeneration. A variety of etiologies, which vary among patients, contributes to this syndrome. (From Harrison's Principles of Internal Medicine, 13th ed, p1611).

Research Excerpts

ExcerptRelevanceReference
"Thalidomide is being investigated for its potential use in treating HIV wasting syndrome and other HIV-related conditions."3.70Clinical pharmacology of thalidomide. ( Trapnell, CB, 1998)
" Thalidomide (Synovir), developed by Celgene, has received limited approval for the treatment of leprosy."3.70FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration. ( Highleyman, L, 1998)
"Thalidomide therapy was associated with mild to moderate rashes and fevers, but not peripheral neuropathy."2.69Thalidomide for the treatment of AIDS-associated wasting. ( Fessel, WJ; Fierer, DS; Haslett, PA; Kaplan, G; Kook, KA; Mulligan, K; Schambelan, M; Smith, LG; Stirling, D; Thomas, S, 2000)
"Although the HIV wasting syndrome has become a far less common manifestation of advanced disease since the introduction of highly active therapies, much has been learned about a number of potential therapeutic interventions."2.41Potential interventions for HIV/AIDS wasting: an overview. ( Abrams, DI, 2000)
"Thalidomide is a drug associated with devastating side effects."1.30Thalidomide's long and winding road. ( Hanna, L, 1998)
"Thalidomide has shown promise in treating wasting and contact information is provided for a compassionate use program."1.30Approaches to the AIDS Wasting Syndrome. ( Corcoran, C, 1998)

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's20 (80.00)18.2507
2000's5 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Woolard, S1
Anand, G1
Sharp, M1
Getty, J1
Klausner, JD1
Brower, V1
Wanke, C1
Bronner, GM1
Koks, CH1
Beijnen, JH1
Corcoran, C2
Grinspoon, S1
Kaplan, G1
Thomas, S1
Fierer, DS1
Mulligan, K1
Haslett, PA1
Fessel, WJ1
Smith, LG1
Kook, KA1
Stirling, D1
Schambelan, M1
Abrams, DI1
MacDougall, DS3
Trapnell, CB1
Hanna, L1
Highleyman, L1
Osoegawa, M1
Kira, J1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT00006158]Phase 20 participants Interventional1998-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

5 reviews available for thalidomide and HIV Wasting Syndrome

ArticleYear
Wasting syndrome in HIV/AIDS patients. A guide to prevention and management.
    Advance for nurse practitioners, 2001, Volume: 9, Issue:9

    Topics: Anti-HIV Agents; Appetite Stimulants; CD4 Lymphocyte Count; HIV Wasting Syndrome; Human Growth Hormo

2001
Single-agent/combination therapy of human immunodeficiency virus-related wasting.
    Seminars in oncology, 1998, Volume: 25, Issue:2 Suppl 6

    Topics: Anabolic Agents; Androgens; Appetite Stimulants; Drug Therapy, Combination; Growth Hormone; HIV Wast

1998
Treatments for wasting in patients with the acquired immunodeficiency syndrome.
    The New England journal of medicine, 1999, Jun-03, Volume: 340, Issue:22

    Topics: Appetite Stimulants; Dietary Supplements; Exercise; Female; HIV Wasting Syndrome; Human Growth Hormo

1999
Potential interventions for HIV/AIDS wasting: an overview.
    Journal of acquired immune deficiency syndromes (1999), 2000, Oct-01, Volume: 25 Suppl 1

    Topics: Anabolic Agents; Anti-HIV Agents; Appetite Stimulants; Clinical Trials as Topic; Female; HIV Wasting

2000
[HIV wasting syndrome].
    Ryoikibetsu shokogun shirizu, 2001, Issue:35

    Topics: Antiretroviral Therapy, Highly Active; Diagnosis, Differential; Growth Hormone; HIV Wasting Syndrome

2001

Trials

2 trials available for thalidomide and HIV Wasting Syndrome

ArticleYear
Thalidomide for the treatment of AIDS-associated wasting.
    AIDS research and human retroviruses, 2000, Sep-20, Volume: 16, Issue:14

    Topics: Adult; Anti-HIV Agents; Body Composition; Body Weight; CD4 Lymphocyte Count; Double-Blind Method; En

2000
Thalidomide trial for diarrhea.
    AIDS patient care and STDs, 1996, Volume: 10, Issue:4

    Topics: Drug Monitoring; HIV Wasting Syndrome; Humans; Immunosuppressive Agents; Randomized Controlled Trial

1996

Other Studies

18 other studies available for thalidomide and HIV Wasting Syndrome

ArticleYear
How drug's rebirth as treatment for cancer fueled price rises.
    Wall Street journal (Eastern ed.), 2004, Nov-15

    Topics: Drug Industry; HIV Wasting Syndrome; Humans; Multiple Myeloma; Neoplasms; Thalidomide

2004
Thalidomide use is associated with weight gain in HIV-1-positive clients.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1997, Aug-15, Volume: 15, Issue:5

    Topics: Adult; Female; HIV Infections; HIV Wasting Syndrome; HIV-1; Humans; Immunosuppressive Agents; Male;

1997
Thalidomide checks might have saved Redux.
    Nature biotechnology, 1997, Volume: 15, Issue:12

    Topics: Appetite Depressants; Drug Approval; Fenfluramine; Heart Valve Diseases; HIV Wasting Syndrome; Patie

1997
A cautious comeback for thalidomide.
    Harvard health letter, 1998, Volume: 23, Issue:4

    Topics: Abnormalities, Drug-Induced; Antineoplastic Agents; Graft vs Host Disease; HIV Wasting Syndrome; Hum

1998
Thalidomide pros and cons.
    The American journal of nursing, 1998, Volume: 98, Issue:4

    Topics: Double-Blind Method; Female; HIV Infections; HIV Wasting Syndrome; Humans; Immunosuppressive Agents;

1998
[Thalidomide once more in the spotlight].
    Nederlands tijdschrift voor geneeskunde, 1999, Jan-09, Volume: 143, Issue:2

    Topics: Adult; Dermatologic Agents; Drug Approval; Female; HIV Wasting Syndrome; Humans; Immunosuppressive A

1999
Positive results reported for thalidomide in AIDS wasting.
    AIDS patient care and STDs, 1997, Volume: 11, Issue:4

    Topics: Body Weight; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; HIV Wasting Sy

1997
Measurement of body composition: the search for a standard.
    Journal of the International Association of Physicians in AIDS Care, 1997, Volume: 3, Issue:1

    Topics: Adult; Biomarkers; Body Water; Extracellular Space; Female; HIV Infections; HIV Wasting Syndrome; Hu

1997
Weight loss update.
    PI perspective, 1996, Issue:No 20

    Topics: AIDS-Related Opportunistic Infections; Appetite Stimulants; Female; Growth Hormone; HIV Infections;

1996
Thalidomide study.
    Project Inform perspective, 1997, Issue:22

    Topics: Clinical Trials as Topic; Drug Approval; HIV Wasting Syndrome; Humans; Oral Ulcer; Placebos; Pregnan

1997
NIH conference on AIDS wasting syndrome. National Institutes of Health.
    Journal of the International Association of Physicians in AIDS Care, 1997, Volume: 3, Issue:8

    Topics: Appetite; Body Composition; Child; Energy Metabolism; Exercise; HIV Infections; HIV Wasting Syndrome

1997
The rehabilitation of thalidomide.
    Journal of the International Association of Physicians in AIDS Care, 1998, Volume: 4, Issue:1

    Topics: Abnormalities, Drug-Induced; CD4 Lymphocyte Count; Conflict of Interest; Contraception; Drug Approva

1998
Clinical pharmacology of thalidomide.
    AIDS clinical care, 1998, Volume: 10, Issue:1

    Topics: Half-Life; HIV Wasting Syndrome; Humans; Hydrolysis; Stereoisomerism; Teratogens; Thalidomide

1998
Thalidomide's long and winding road.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1998

    Topics: Abnormalities, Drug-Induced; Clinical Trials as Topic; Drug Approval; Female; Health Services Access

1998
The thalidomide comeback.
    HIV hotline, 1998, Volume: 8, Issue:2

    Topics: AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV Infection

1998
Approaches to the AIDS Wasting Syndrome.
    Positive Directions news : a support and information network of people with HIV/AIDS, their families, friends and providers, 1998,Summer, Volume: 10, Issue:2

    Topics: AIDS-Related Opportunistic Infections; Anabolic Agents; Appetite Stimulants; Dronabinol; Exercise; F

1998
Simply stated...are people still wasting?
    Research initiative, treatment action : RITA, 1998, Volume: 4, Issue:5

    Topics: AIDS-Related Opportunistic Infections; Appetite Stimulants; Energy Intake; Growth Hormone; HIV Infec

1998
FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1998

    Topics: 2-Aminopurine; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; D

1998